Interesting CRSP Put And Call Options For November 7th

The article details options strategies for CRISPR Therapeutics (CRSP), currently trading at $61.10. Selling a $50.00 put contract offers a potential 20.35% annualized return (YieldBoost) if it expires worthless (79% probability), targeting an effective entry price of $48.80. Alternatively, a covered call strategy using a $63.00 strike could yield 5.97% by November 7th if shares are called away, or a 24.29% annualized YieldBoost if the call expires worthless (57% probability), with implied volatilities for the put and call at 80% and 66% respectively, against a 59% historical volatility.

Analysis

The options market for CRISPR Therapeutics (CRSP), currently trading at $61.10, presents distinct opportunities for income generation and strategic position entry. Selling a cash-secured put at the $50.00 strike offers a way to establish a position at an effective cost basis of $48.80, an 18% discount to the current share price, should the stock decline. Alternatively, if the contract expires worthless, which has a stated probability of 79%, the seller would realize a 20.35% annualized return on the cash commitment. For existing shareholders, a covered call strategy at the $63.00 strike could generate a 5.97% total return by the November 7th expiration if the shares are called away, or an annualized yield of 24.29% from the premium if the option expires worthless (a 57% probability). A key data point is the divergence between implied and historical volatility; the implied volatility of the put (80%) and call (66%) are both elevated compared to the stock's 59% actual trailing twelve-month volatility. This suggests options are pricing in a larger-than-historical price swing, making premium-selling strategies appear relatively attractive if that volatility fails to materialize.

Key Decisions for Investors

• Bullish investors seeking a lower entry point on CRSP could consider selling the $50.00 strike put to either acquire shares at a significant discount or generate a 20.35% annualized yield.
• Current shareholders aiming to generate income could sell the $63.00 strike covered call, but must be willing to cap their potential upside at a 5.97% total return by the November expiration.
• Investors should note that the elevated implied volatility (66%-80%) relative to historical volatility (59%) presents a favorable environment for option sellers, assuming the stock's price action remains less volatile than the market currently anticipates.